• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany

tetano

Editor, Senior Moderator
Influenza Other Respi Viruses. 2013 Aug 20. doi: 10.1111/irv.12152. [Epub ahead of print]
Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.
Reuss A, Dehnert M, Buda S, Haas W.
Source

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Abstract
BACKGROUND:

The World Health Organization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness.
OBJECTIVES:

The aim of this study was to determine the proportion of cases with laboratory-confirmed A(H1N1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (H1N1) 2009 and to investigate factors associated with the use of antivirals.
METHODS:

We analyzed cases with laboratory-confirmed A(H1N1)pdm09 infection notified to national health authorities in Germany between week 29/2009 and week 17/2010 using multivariable logistic regression. Severity of disease was defined by pneumonia or death.
RESULTS AND CONCLUSIONS:

Of 160 804 cases with laboratory-confirmed A(H1N1)pdm09 infection, 22% were treated with antivirals. Cases with severe disease were more likely to be treated with antivirals than cases without severe disease (odds ratio = 1?66; 95% confidence interval: 1?46-1?89). In the group with at least one underlying medical condition, only children aged between 1 and 4 years had significant lower odds for receiving antiviral treatment compared with cases in the age group 15 to 49 years (odds ratio = 0?75; 95% confidence interval: 0?6-0?94). In conclusion, the implementation of international recommendations on use of antivirals differed according to the age of patients in Germany during the pandemic (H1N1) 2009. This indicates that the potential of antivirals to prevent severe influenza might not have been fully exhausted. The reasons leading to the observed differences in patient management need to be investigated.

? 2013 John Wiley & Sons Ltd.
KEYWORDS:

A(H1N1)pdm09, H1N1 subtype, age groups, antiviral agents, influenza A virus

PMID:
23957666
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23957666
 
Back
Top Bottom